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Folate is required for DNA synthesis, repair and methylation. Low folate status has been implicated in carcinogenesis, possibly as a
result of higher rate of genetic damage. The aim of this study is to compare folate status and levels of DNA damage between breast
cancer and benign breast disease control patients. Fasting blood samples from 64 histologically confirmed untreated breast cancer
patients (mean age 57 years) and 30 benign breast disease control patients (mean age 51 years) were obtained. Red cell folate (RCF)
and plasma homocysteine were measured. Mononuclear cells (MNC) were isolated for genetic damage analysis using the basic
alkaline comet assay. Results are expressed as tail moment. Data were log transformed as appropriate before analysis for
normalisation purposes. The geometric mean (95% confidence interval) of RCF (ngml
 1) in breast cancer patients was 339.07
(333.3–404.6) vs 379.5 (335.8–505.2) in control patients (P¼0.24). Corresponding plasma homocysteine concentrations (mmoll
 1)
were 11.9 (10.6–16.4) vs 10.1 (9.3–11.9) (P¼0.073), respectively. The mean tail moment (s.d.) of DNA damage in MNC of breast
cancer patients detected by the basic comet assay was 1.4 (0.66) vs –0.17 (0.79) in controls (Po0.0001, t-test), the modified comet
assay ‘endonuclease III (Endo III)’ was 1.7 (0.70) vs 0.86 (0.81) (Po0.0001, t-test), and the modified comet assay
‘formamidopyrimidine glycosylase (FPG)’ was 1.6 (0.62) vs 0.99 (0.94) (Po0.0001, t-test). There was a significant negative
correlation between RCF levels and DNA damage detected by modified comet assay ‘FPG’ (Pearson Correlation Coefficient
r
2¼ 0.26, P¼0.02) and DNA damage was found to be significantly higher in MNC of breast cancer patients compared to benign
breast disease control patients. Breast cancer patients tended to have lower RCF levels and higher levels of plasma homocysteine, but
these differences were not significant. The study provides preliminary evidence that reduced folate status may be implicated in the
aetiology of breast cancer perhaps by increasing the in vivo level of genetic instability.
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Breast cancer remains one of the most common solid epithelial
neoplasms. In the UK, there is an estimated annual incidence of
20000 new cases per year, with a worldwide incidence of one
million new cases per year (Sainsbury, 1999). Despite the fall in
mortality in recent years, the incidence of breast cancer in the UK
is rising (Sainsbury, 1999).
Collectively, the evidence from epidemiological, animal and
human studies strongly suggests that folate status modulates the
risk of developing cancers in selected tissue, the most notable of
which is the colorectum (Kim, 1999). Folate depletion appears to
enhance carcinogenesis, whereas folate supplementation may
convey a protective effect (Kim, 1999). Recent studies suggest that
folate may play an important role in the prevention of breast
cancer, particularly among women consuming alcohol (Zhang,
2004). The means by which this modulation of cancer risk is
mediated is not known with certainty, but there are several
possible mechanisms (Zhang, 2004). Folate plays an integral role in
DNA synthesis and methylation (Rampersaud et al, 2002). It is
believed that folate deficiency affects DNA stability through two
potential pathways. 5,10-Methylenetetrahydrofolate donates
methyl group to uracil, converting it to thymine, which is used
for DNA synthesis and repair. If folate is limited, imbalances in the
DNA precursors occur, and uracil may be misincorporated into
DNA. Subsequent misincorporation and repair may lead to
double-strand breaks, chromosomal damage and cancer (Duthie
et al, 2002). Folate affects gene expression by regulating cellular
S-adenosylmethionine (SMA) levels. 5-Methyltetrahydrofolate is
the methyl donor in the remethylation process of homocysteine to
methionine, which is converted to SAM. SAM methylates specific
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scytosines in DNA and thus regulates gene transcription. As a
consequence of folate deficiency, cellular SAM is depleted, which
in turn induces DNA hypomethylation and potentially induces
proto-oncogene expression leading to cancer (Duthie et al, 2002).
Epidemiological evidence relating folate intake to breast cancer
is limited. Some case–control studies reported an inverse
association between dietary folate intake and breast cancer risk
(Graham et al, 1991; Freudenheim et al, 1996; Levi et al, 2001).
Graham et al (1991) reported 30% lower risk of breast cancer
among postmenopausal women who consume higher intake of
dietary folate. In another case–control study, premenopausal
women who consumed at least 460mgday
 1 of folate had a
50% lower risk of breast cancer than women who consumed
304mgday
 1 or less (Freudenheim et al, 1996). A Swiss case–
control study also reported a significant inverse association
between folate intake and risk of breast cancer in postmenopausal
women, and this association was stronger in women who
consumed alcohol (Levi et al, 2001). The population-based
Shanghai Breast Cancer Study evaluated the association of dietary
folate intake and breast cancer risk in China between 1996 and
1998 among 25–64 year old women, who never drank alcohol
regularly or used vitamin supplement (Shrubsole et al, 2001).
Dietary folate intake was significantly inversely associated with
breast cancer risk in women who were in the highest
(320mgday
 1) vs lowest (214mgday
 1) quartile of folate intake
(Shrubsole et al, 2001). On the other hand, some case–control
studies have failed to show any protective effect of folate against
breast cancer (Thorand et al, 1998; Potischman et al, 1999; Negri
et al, 2000). One recently published study reported that higher
intakes of folate in early adult life does not reduce the risk of breast
cancer in premenopausal women (Cho et al, 2003).
Despite extensive investigation of the association between
alcohol consumption and breast cancer risk, a concordance of
opinion is not apparent (Kropp et al, 2001). Moreover, there is
evidence from two large epidemiological studies that folate status
may be a factor which affects the association between alcohol
intake and breast cancer risk (Zhang et al, 1999; Rohan et al, 2000).
In the meta-analysis conducted by Longnecker et al (1988), there
was a strong evidence to support a dose–response relation
between breast cancer risk and alcohol intake. A pooled analysis
of six prospective cohort studies conducted in Canada, the
Netherlands, Sweden and the US, which included 322,647 women
with 4335 cases of breast cancer diagnosed during the 11 years of
follow-up period, reported results which were not clearly
supportive that alcohol consumption is associated with breast
cancer incidence (Smith-Warner et al, 1998).
Although there is some evidence to link lower folate to a higher
risk of breast cancer, the evidence is not entirely consistent and
most reported studies evaluated folate only on the basis of dietary
intake data. The aim of this study was to compare the folate status
measured by red cell folate (RCF) concentrations in breast cancer
and control patients, and to relate this to levels of DNA damage in
both groups.
Patient recruitment
Ethical approval for this cross-sectional study was granted by the
Research Ethical Committee of Queen’s University of Belfast. All
patients gave written informed consent. Patients were recruited
from the Breast Surgery Unit, Belfast City Hospital between August
2000 and August 2001. All patients undergoing surgery in the
Breast Surgery Unit during the study period (300 breast cancer
patients) were screened for potential inclusion in the study. The
diagnosis of breast cancer and benign breast disease were
histologically confirmed. Benign breast disease patients required
surgery either at their own request or due to repeated episodes of
inflammation around the nipple and areola (duct ectasia). A total
of 64 pre- and postmenopausal breast cancer patients (cases) and
30 benign breast disease patients (controls) were recruited. All
patients and controls were recruited within 3 weeks of the
histological diagnosis. All patients were asked to complete a short
questionnaire including past medical history, drug history and
basic lifestyle questionnaire that included details about alcohol
consumption and smoking.
The inclusion criteria were histologically confirmed pre- and
postmenopausal breast cancer patients prior to any treatment and
histologically confirmed pre- and postmenopausal benign breast
disease patients.
Exclusion criteria were patients taking any vitamin supplements,
or those with gastrointestinal disease (including inflammatory
bowel disease, malabsorption, coeliac disease) and patients with
previous gastric or intestinal surgery. Patients taking medications
known to interfere with folate metabolism, for example, anti-
epileptics, oral contraceptive pills and sulfasalazine, were also
excluded. In addition, we excluded patients with ductal carcinoma
in situ (DCIS) and patients with benign breast diseases that are
known to increase the risk of breast cancer including ductal or
lobualr epithelial hyperplasia.
Laboratory methods
A fasting blood sample (30ml) was collected in the early morning
before surgery for subsequent analysis of folate status (15ml EDTA
tube) and for isolation of mononuclear cells (MNC) (15ml lithium
heparin-coated tube) for DNA damage analysis. The patients then
underwent surgery. A RCF lysate was prepared by diluting blood
1:10 with freshly prepared 1% ascorbic acid solution, wrapped in
foil and mixed for 30min, then stored at  801C. Full blood picture
analysis, including packed cell volume (required for the calculation
of RCF concentration, that is, RCF¼whole blood folate divided by
packed cell volume) was measured in the remaining whole blood
using an automated counter in Belfast City Hospital Trust
Laboratories. All samples were stored at  801C for batch analysis
at the end of the study.
Mononuclear cells were separated within an hour of blood
sample collection. The cell pellet was suspended in 1ml the Hanks
Balanced Salt Solution (HBSS) (Gibco, UK) and the cells were
counted using a haemocytometer or by automatic cell counter to
ensure a concentration of 2–3 10
6 cellsml
 1. Cell viability was
checked using trypan blue (which stains dead cells a deep blue
colour) to ensure viability of 80–90%. The cells were mixed with a
freeze down medium (1.3ml HBSS, 0.2ml dimethyl sulphoxide and
0.56ml autologous serum). This solution was transferred to  861C
freezer and subsequently into liquid nitrogen after 24h for long-
term storage.
The relationship between DNA damage markers and folate
status was examined in both cases and controls by analysis of the
blood samples for RCF levels using the microbiological assay
(Molloy and Scott, 1997) and plasma homocysteine levels using the
immunoassay (Leino, 1999). DNA damage biomarkers were
measured in the MNC using the alkaline comet assay (Singh
et al, 1988) and the modified comet assay (Collins et al, 1993) as
described below.
Measurement of DNA damage: single cell gel
electrophoresis (comet) assay
Levels of DNA damage (DNA single-strand breaks and alkali-labile
lesions) in T-cell clones were determined using the alkaline comet
assay, according to the method of Singh et al (1988), and also the
modified alkaline comet assay described by Collins et al (1993).
In the modified comet assays, T cells embedded on slides were
treated with either formamidopyrimidine glycosylase (FPG), which
recognises oxidatively modified purines (Boiteux et al, 1992), or
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swith endonuclease III (ENDO III), which recognises oxidatively
modified pyrimidines (Asahara et al, 1989). These enzymes nick
DNA at the sites of oxidatively damaged nucleotides, creating
single-strand breaks which can be detected with the alkaline comet
assay. T cells treated with 150mM hydrogen peroxide for 5min at
41C (to induce oxidative DNA damage) were used as internal
positive controls in the modified alkaline comet assay to verify
enzyme activity.
The comet assays were performed at 41C to minimise the repair
of existing basal levels of DNA damage present in the T cells. Cells
were embedded in a 1% agarose gel on frosted microscope slides
(2 10
4 cellsgel
 1), and lysed for at least 1h in a high salt alkaline
buffer (2.5 M NaCl, 0.1 M EDTA, 0.01 M Tris, 1%(vv
 1) Triton
X-100, pH 10). For the modified comet assay, slides were then
equilibrated in enzyme buffer (0.04 M HEPES, 0.1 M KCl, 0.5mM
EDTA, 0.2mgml
 1 BSA, pH 8.0) prior to application of FPG or
ENDO III. Slides treated with the lesion-specific enzymes were
incubated at 371C in a humid dark chamber for 45min. Following
enzyme treatment (or directly after alkaline lysis in the case of the
alkaline comet assay), the slides were placed in electrophoresis
buffer (0.3 M NaOH, 1mM EDTA, pH 13) for 40min. This period of
incubation is to allow unwinding of DNA to be initiated from
strand breaks, and then electrophoresis current is applied at 25V,
300mA, for 30min. Following electrophoresis, the slides were
neutralised using 0.4 M Tris pH 7.5 and stained with 50mlo f
20mgml
 1 ethidium bromide. Stained slides were digitally
analysed using UV microscopy and Komet 3.0 analysis software
(Kinetic Imaging, UK), counting 50 cells per slide. DNA damage
results were expressed as percentage DNA in the comet tail.
Internal controls An established stable cell line was used as an
internal control for all comet assays. The cells are lymphoblastoid
human T-lymphocyte cells, RJK 853 clones (Yang et al, 1984; Beare
et al, 1993). These internal control cells were used to demonstrate
the reproducibility of the technique, and to calculate the coefficient
of variation (CV) of each experiment (CV¼standard deviation/
mean).
Statistics
All statistical analysis was performed using the statistics package
for the Social Sciences (SPSS) version 10 computer software
package (Chersey, UK). For all statistical tests, P-values o0.05
were considered significant. Plasma homocysteine, RCF and DNA
damage (tail moment) data were skewed and were log transformed
to normalise the data for comparison (which was subsequently
performed using the t-test). Correlation analysis was performed at
the log scale using the Pearson Correlation.
RESULTS
Although breast cancer and control patients were not singularly
matched, their distribution was homogenous and no adjustment
for anthropometric measurements, age or menopausal status was
needed (Table 1). All patients had no high-risk family history of
breast cancer. A total of 42 patients did not consume alcohol (26
cancer patients and 16 controls) (Table 1).
All patients recruited for the control group had histologically
confirmed benign breast conditions. There were 13 fibroadeno-
mata, nine benign inflammatory lesions, four breast reductions/
nipple eversions, two lipomata and two sebaceous cysts of the
breast. Patients with a fibroadenoma had a surgical excision due to
their own request. Inflammatory lesions of the breast were all due
to mammary duct ectasia. The postoperative histopathology of all
surgically removed specimens confirmed benign breast disease
with no evidence of cellular atypia or hyperplasia.
The mean value (95% confidence interval) of RCF of breast
cancer patients was 369.0 (333.3–404.6)ngml
 1 compared to 420.5
(335.8–505.2)ngml
 1 for control patients. As the RCF values were
skewed (positively skewed in control patients towards higher
values, and negatively skewed in breast cancer patients towards
lower values), all values were log transformed to normalise the data
for comparison. Red cell folate levels for breast cancer patients and
controls are shown in Table 2.
The mean value (95% confidence interval) of plasma homo-
cysteine of breast cancer patients was 13.5 (10.6–16.4)mmoll
 1
compared to 10.6 (9.3–11.9)mmoll
 1 for control patients. The
plasma homocysteine values were also skewed, and were log
transformed to normalise the data for comparison. Results were
presented as geometric mean (95% confidence interval of the
geometric mean) and compared by using the t-test (Table 2).
Although the results were not statistically significant, breast cancer
patients tended to have lower RCF and higher plasma homo-
cysteine levels than control patients.
DNA damage analysis
Following the basic alkaline comet assay, the mean (s.d.) tail
moment for breast cancer patients was 5.0 (3.4) vs 1.1 (1.2) for
control patients. The mean (s.d.) tail moment detected by the
modified comet assay using Endonuclease III (which detects
additionally oxidised pyrimidins) for breast cancer patients was
7.5 (6.2) vs 3.1 (2.3) for control patients. The mean (s.d.) tail
moment detected by the modified comet assay using formamido-
pyrimidine glycosylase ‘FPG’ (which detects additionally oxidised
purines) for breast cancer patients was 6.3 (3.6) vs 3.7 (2.7) for
control patients.
Table 1 Characteristics of breast cancer and control patients
Breast
Cancer (s.d.)
Control
(s.d.)
Significance
(t-test)
Mean age (years) 57 (14.3) 51 (14.1) P¼0.08
Weight (kg) 69.1 (12.8) 68.7 (11.6) P¼0.86
Height (m) 1.60 (0.05) 1.59 (0.06) P¼0.29
BMI (kgm
 2) 26.6 (4.7) 27.1 (4.9) P¼0.67
Menopausal status
Premenopausal 21 14 P¼0.26
a
Postmenopausal 43 16
Alcohol consumption (gday
 1) 3.49 (4.39) 4.69 (7.7) P¼0.34
Smoking P¼0.82
a
Nonsmokers 55 27
Smokers 9 3
aw
2 test s.d.¼standard deviation.
Table 2 Blood folate status measurements in breast cancer and control patients
Variable Breast cancer geometric mean (95% CI) Controls geometric mean (95% CI) Significance (Student’s t-test)
Red cell folate (ngml
 1) 339.07 (303.9–378.3) 379 (322.8–446.3) P¼0.246
Plasma homocysteine (mmoll
 1) 11.90 (10.61–13.25) 10.14 (9.01–11.43) P¼0.073
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sThe tail moment values were highly positively skewed and for
the purpose of normalisation, these were log transformed. The data
were presented as log mean tail moment (Table 3).
Figure 1 shows the overall frequency distribution of DNA
damage in the MNC in all slides analysed for breast cancer and
control patients. It shows that 97% of MNC from control patients
had tail moment values of 0–5, and 3% of the cells showed tail
moment values of 5–10. On the other hand, mononuclear cells
from breast cancer patients had a larger percentage of their cells in
the higher tail moment categories, indicating more DNA damage
(59% of these cells showed tail moment value of 0–5, 29% showed
tail moment values of 5–10, 8% showed tail moment of 10–15 and
4% of the cells showed tail moment values of 415). A similar
pattern was observed in samples processed by the modified comet
assays, with a larger percentage of cells showing higher tail
moment values in breast cancer than control patients.
Tail moment of RJK853 internal control cells was not skewed
and was not log transformed. The mean (s.d.) tail moment of
internal control cells detected by basic comet assay was 1.7 (1.2)
and the coefficient of variation (CV) was 0.71. The mean (s.d.) tail
moment of internal control cells detected by modified comet assay
(Endonuclease III) was 3.5 (2.9) and the CV was 0.82, and for FPG
enzyme was 4.8 (3.7) and the CV was 0.77. This shows that the CV
was (0.71–0.82) and demonstrated that the technique is highly
reproducible. It also proved good laboratory practice and evidence
for the ability to compare breast cancer and control patients as the
DNA damage induced by the technique of comet assay itself was
minimal.
Correlation analysis Correlation analysis was performed between
plasma homocysteine or RCF status of all patients (including
breast cancer and control patients) and DNA damage levels in
MNC of all patients at the log scale (using Pearson Correlation).
There was a significant negative correlation between RCF values
and DNA damage detected by the modified comet assay using FPG
enzyme. There was no significant correlation between plasma
homocysteine of all patients and DNA damage (Table 4).
Impact of alcohol intake on DNA damage and folate status Pa-
tients who consumed alcohol (total 52 patients, 38 breast cancer
and 14 control patients) were divided into two groups according to
their folate status. For the purpose of comparison, folate status was
considered to be low if the RCF level was less than the median
value (363.98ngml
 1), and folate status high if the RCF was higher
than the median value. Pearson Correlation was performed
between log tail moment and log alcohol intake. In breast cancer
patients who had low RCF values, there was a significant positive
correlation between log alcohol intake and log tail moment
detected by the modified comet assay (FPG) (Pearson Correlation
Coefficient¼0.58, P¼0.04). In control patients who had low RCF
values, there was no significant correlation between alcohol intake
and DNA damage (Table 5).
In breast cancer patients who had high RCF values, there was a
significant positive correlation between log alcohol intake and log
tail moment detected by the modified comet assay (Endo III)
(Pearson Correlation Coefficient¼0.67, P¼0.01) and log tail
moment detected by the modified comet assay (FPG) (Pearson
Correlation Coefficient¼0.58, P¼0.04). In control patients who
had high RCF values, there was no significant correlation between
alcohol intake and DNA damage (Table 5).
There was no significant correlation between log alcohol intake
and log RCF in breast cancer patients (Pearson Correlation
Table 3 Levels of DNA damage in mononuclear cells of breast cancer and control patients
Variable Breast cancer mean log TM (s.d.) [95% CI] Control mean log TM (s.d.) [95% CI] Significance (Student t-test)
1. Basic alkaline comet 1.46 (0.66) [1.26–1.66]  0.177 (0.79) [ 0.43–0.08] Po0.0001*
2. Modified comet (Endo III) 1.77 (0.70) [1.56–1.98] 0.86 (0.81) [0.59–1.13] Po0.0001*
3. Modified comet (FPG) 1.67 (0.62) [1.46–1.88] 0.99 (0.94) [0.72–1.26] Po0.0001*
*Significant (t-test). (s.d.)¼standard deviation; 95% CI¼95% confidence interval; TM¼tail moment¼migrated DNA tail length; Endo III¼endonuclease III enzyme (to detect
oxidised pyrimidines); FPG¼formamidopyrimidine glycosylase enzyme (to detect oxidised purines).
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Figure 1 Frequency distribution of DNA damage in MNC of breast
cancer and control patients. A greater percentage of the cells from the
breast cancer patients had DNA damage levels in the highest damage
categories of the frequency distributions. DNA damage expressed as tail
moment¼migrated DNA tail length.
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2¼0.05, P¼0.73) or in control patients (Pearson
Correlation Coefficient r
2¼ 0.25, P¼0.37).
DISCUSSION
This study aimed to compare folate status and levels of DNA
damage between breast cancer and benign breast disease (control)
patients. Folate status was evaluated using RCF and plasma
homocysteine, and DNA damage in the MNC was evaluated using
the comet assay. Breast cancer patients tended to have a reduced
folate status, that is, lower RCF and higher plasma homocysteine
levels than control patients, but this failed to reach statistical
significance. DNA damage in MNC of breast cancer patients was
significantly higher than that of the control patients. Red cell folate
was negatively correlated with DNA damage detected by the
modified comet assay (using FPG enzyme). Alcohol intake was
positively correlated (independent of folate status) with the level of
DNA damage detected by the modified comet assay in breast
cancer, but not the control patients. We were unable to
demonstrate an interaction between folate status and alcohol
intake in breast cancer or control patients.
The most frequently selected indicator of folate status is the
erythrocyte folate level. Other indicators include serum and plasma
folate levels (Jacques et al, 1993). The main limitation of serum and
plasma folate levels is that they reflect transient changes in folate
intake. The circulating folate concentration may be reduced in
situations where there is no alteration in the overall status such as
acute alcohol ingestion (Jacques et al, 1993). Folate is taken up
only by the developing erythrocyte in the bone marrow, and
therefore RCF is a good indicator of the long-term folate status
(WU et al, 1975). Plasma homocysteine concentration increases
when inadequate quantities of folate are available for the
remethylation of homocysteine to methionine. Therefore, it is
used as another indicator of folate status (Selhub et al, 1993).
Although the current pilot study did not demonstrate a significant
difference in RCF and plasma homocysteine concentrations, there
is a possibility that a true difference might exist but was not
demonstrated because of the small sample size in the study.
There is lack of data studying RCF and plasma homocysteine
concentrations in breast cancer patients. One study investigated
the incidence of breast cancer and the prediagnostic serum level of
folate and homocysteine using serum specimens from the
Washington County serum bank donated between 1974 and 1989
(Wu et al, 1999). Breast cancer cases (195 patients) were identified
and were matched to 195 control subjects. There was no evidence
for an association between serum folate or homocysteine levels and
risk of breast cancer. There was no significant difference between
the odds ratio of breast cancer for patients in the highest quartile
of serum folate and that for patients in the lowest quartile.
However, only nonfasting blood samples were available, which is
known to affect the serum folate and homocysteine levels, and
there are possible adverse effects of storage on the stored samples
(Wu et al, 1999). A study recently reported by Beilby et al (2004)
evaluated the folate status and the methylenetetrahydrofolate
reductase (MTHFR) genotype of 141 breast cancer patients and 109
age-matched controls. The authors reported that serum folate was
significantly lower in cancer patients and that the increased serum
concentration of folate due to MTHFR polymorphism was
associated with reduced risk of breast cancer (Beilby et al, 2004).
These two studies used serum folate, in contrast to our study which
used RCF, as a marker of the folate status.
In the study being reported in this paper, the alkaline comet
assay was used to investigate the level of DNA damage in MNC.
This was significantly higher in breast cancer patients compared to
the controls. We used the modified alkaline comet assay described
by Collins et al (1993) to increase the sensitivity of the assay by
additionally measuring the oxidised pyrimidine or purine bases.
The Endo III and the FPG enzymes recognize oxidatively damaged
pyrimidines and purines, respectively, and nick the DNA at these
sites creating single-strand breaks, which can be detected by the
comet assay, thus increasing the sensitivity of the assay (Collins
et al, 1993). In this study, the levels of DNA damage detected by
basic and modified comet assay were significantly higher in breast
cancer patients than controls. We studied the effect of folate status
on DNA damage by correlation analysis. The negative correlation
was only significant for the DNA damage detected by FPG enzyme,
which demonstrate the significance of increasing the sensitivity of
the assay. The study conducted in vitro by Duthie et al (2002)
reported that folate deficiency increased DNA damage in cultured
human lymphocytes and the DNA instability was inversely related
to the concentration of folic acid available to the cells, and also
demonstrated the sensitivity of the modified comet assay. These
findings, as well as our result may indicate that the intake of folate
Table 4 Correlation between folate status and levels and DNA damage
in mononuclear cells of all patients
Log mean tail moment
Variable
Basic Comet
Mean (s.d.)
0.82 (1.06)
Endo III
Mean (s.d.)
1.39 (0.85)
FPG
Mean (s.d.)
1.36 (0.82)
Red cell folate
Pearson Correlation (r
2)  0.155  0.157  0.26*
(significance) (P¼0.18) (P¼0.18) (P¼0.02)*
Plasma homocysteine
Pearson Correlation (r
2) 0.08 0.06 0.08
(significance) (P¼0.48) (P¼0.58) (P¼0.48)
*Significant (Pearson Correlation). TM¼tail moment¼migrated DNA tail length;
Endo III¼endonuclease III enzyme; FPG¼formamidopyrimidine glycosylase enzyme.
Table 5 Correlation between alcohol intake and DNA damage in
mononuclear cells of breast cancer and control patients who had low and
high red cell folate (RCF) values
Log mean tail moment
Basic Comet Endo III FPG
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Log alcohol intake (gday
 1) 0.82 (1.06) 1.39 (0.85) 1.36 (0.82)
Low red cell folate
Breast cancer
Pearson Correlation (r
2) 0.25 0.36 0.58
(Significance) (P¼0.42) (P¼0.24) (P¼0.04)*
Controls
Pearson Correlation (r
2)  0.32  0.17  0.57
(Significance) (P¼0.42) (P¼0.68) (P¼0.13)
High RCF
Breast cancer
Pearson Correlation (r
2) 0.4 0.67 0.58
(Significance) (P¼0.19) (P¼0.01)* (P¼0.04)*
Controls
Pearson Correlation (r
2)  0.007  0.21  0.75
(Significance) (P¼0.99) (P¼0.72) (P¼0.13)
*Significant (Pearson Correlation). Low red cell folate (RCF)¼less than median RCF
value¼363.98ngml
 1. High red cell folate (RCF)¼more than median RCF
value¼363.98ngml
 1.
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for maintaining DNA stability.
Another study has investigated the level of DNA damage, using
the basic comet assay, in leucocytes of 88 breast cancer patients
and 121 healthy controls as well as in 188 first-degree female
relatives of breast cancer patients (Rajeswari et al, 2000). The
authors reported that the maximum leucocyte DNA damage was
observed in the breast cancer patients. The DNA damage in the
leucocytes of the first-degree female relatives was 2.5 times higher
compared to that of the healthy controls. The authors used the
mean comet tail length (mm) as a measure of DNA damage, in
contrast to this present study which used the mean tail moment
(migrated DNA   tail length), so direct comparison of the results
is not possible (Rajeswari et al, 2000). However, the previous study
showed that the DNA damage was significantly higher in
leucocytes from breast cancer patients compared to controls,
which agrees with our findings.
In the current study, there was no significant association
between alcohol intake and breast cancer risk, possibly because a
large proportion of women did not consume alcohol, the relatively
low-alcohol consumption and the relatively small number of
patients in the study. Our results agree with several other studies
which have reported lack of association of breast cancer with low-
to-moderate alcohol consumption (Nasca et al, 1990; Howe et al,
1991; Sneyd et al, 1991; Longnecker et al, 1995; Swanson et al,
1997; Stoll, 1999; Rohan et al, 2000; Kropp et al, 2001). In the case–
control study conducted by Kropp et al (2001) in Germany, which
included 706 premenopausal breast cancer patients and 1381
controls, provided evidence that low-to-moderate level of alcohol
consumption does not increase breast cancer risk. However, there
was a significantly increased risk of breast cancer for alcohol
intake of more than 31gday
 1.
Several investigators have examined the association between
total folate intake and breast cancer risk by levels of alcohol
consumption (Zhang et al, 1999; Rohan et al, 2000; Sellers et al,
2001). The Nurses Health Study demonstrated a significant
positive association between alcohol intake and breast cancer risk,
with a 24% increased risk among women consuming at least
15gday
 1 alcohol compared to nondrinkers (Zhang et al, 1999).
Another cohort study from the Mayo Clinic, conducted by Sellers
et al (2001) reported that women with low dietary folate (less than
186mgday
 1) and alcohol intake, more than 4gday
 1, had a 59%
increased risk of breast cancer. The cohort study conducted by
Rohan et al (2000) reported that in women who consumed more
than 14gday
 1 of alcohol, women with low folate intake (less than
224mgday
 1) had a higher risk of breast cancer compared to
women with high folate intake (more than 354mgday
 1). In the
current study, patients who consumed alcohol were divided into
low and high folate groups according to their RCF levels. There
was a trend of a positive correlation between alcohol intake and
DNA damage in breast cancer but not the control patients
irrespective of their RCF status. This could be due to relatively low
alcohol consumption and the small number of patients in this
study.
In conclusion, DNA damage levels were found to be significantly
higher in MNC of breast cancer patients compared to benign
breast disease control patients. Breast cancer patients tended to
have lower RCF and higher plasma homocysteine concentrations,
but these differences were not statistically significant. There was
evidence of a negative correlation between DNA damage and RCF
in all patients. There was evidence of a positive correlation
between DNA damage and alcohol intake in breast cancer, but not
the control patients. However, this correlation was not affected by
RCF status possibly as a result of the small numbers of patients in
this study and relatively low alcohol consumption.
This is the first study to investigate the level of DNA damage and
folate status in breast cancer and benign breast disease patients,
providing some evidence that reduced folate may be implicated in
the development of breast cancer.
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